Omar Hasan Ali
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
02.09.2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
02.09.2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells.
Garreta E, Prado P, Stanifer M, Monteil V, Marco A, Ullate-Agote A, Moya-Rull D, Vilas-Zornoza A, Tarantino C, Romero J, Jonsson G, Oria R, Leopoldi A, Hagelkruys A, Gallo Cantafio M, González F, Domingo-Pedrol P, Gavaldà A, Del Pozo C, Hasan Ali O, Ventura-Aguiar P, Campistol J, Prosper F, Mirazimi A, Boulant S, Penninger J, Montserrat N. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metab 2022; 34:857-873.e9.
12.05.2022A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells.
12.05.2022Cell Metab 2022; 34:857-873.e9
Garreta Elena, Prado Patricia, Stanifer Megan L, Monteil Vanessa, Marco Andrés, Ullate-Agote Asier, Moya-Rull Daniel, Vilas-Zornoza Amaia, Tarantino Carolina, Romero Juan Pablo, Jonsson Gustav, Oria Roger, Leopoldi Alexandra, Hagelkruys Astrid, Gallo Cantafio Maria Eugenia, González Federico, Domingo-Pedrol Pere, Gavaldà Aleix, Del Pozo Carmen Hurtado, Hasan Ali Omar, Ventura-Aguiar Pedro, Campistol Josep María, Prosper Felipe, Mirazimi Ali, Boulant Steeve, Penninger Josef M, Montserrat Nuria
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
07.12.2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
07.12.2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Oncoimmunology 2021; 10:2006893.
27.11.2021Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
27.11.2021Oncoimmunology 2021; 10:2006893
Berner Fiamma, Niederer Rebekka, Luimstra Jolien J, Pop Oltin Tiberiu, Jochum Ann-Kristin, Purde Mette-Triin, Hasan Ali Omar, Bomze David, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Dubbelaar MariLisa, Abdou Marie-Therese, Baumgaertner Petra, Appenzeller Christina, Cicin-Sain Caroline, Lenz Tobias, Speiser Daniel E, Ludewig Burkhard, Driessen Christoph, Jörger Markus, Früh Martin, Jochum Wolfram, Cozzio Antonio, Rammensee Hans-Georg, Walz Juliane, Neefjes Jacques, Flatz Lukas
Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.
Hasan Ali O, Bomze D, Risch L, Brugger S, Paprotny M, Weber M, Thiel S, Kern L, Albrich W, Kohler P, Kahlert C, Vernazza P, Bühler P, Schüpbach R, Gómez-Mejia A, Popa A, Bergthaler A, Penninger J, Flatz L. Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis 2021; 73:1746.
02.11.2021Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies.
02.11.2021Clin Infect Dis 2021; 73:1746
Hasan Ali Omar, Bomze David, Risch Lorenz, Brugger Silvio D, Paprotny Matthias, Weber Myriam, Thiel Sarah, Kern Lukas, Albrich Werner, Kohler Philipp, Kahlert Christian, Vernazza Pietro, Bühler Philipp K, Schüpbach Reto A, Gómez-Mejia Alejandro, Popa Alexandra M, Bergthaler Andreas, Penninger Josef M, Flatz Lukas
Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies
Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejia A, Schüpbach R, Bühler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clin Infect Dis 2021; 73:e2869-e2874.
02.01.2021Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies
02.01.2021Clin Infect Dis 2021; 73:e2869-e2874
Hasan Ali Omar, Penninger Josef M, Bergthaler Andreas, Popa Alexandra M, Gómez-Mejia Alejandro, Schüpbach Reto A, Bühler Philipp K, Vernazza Pietro, Kahlert Christian, Kohler Philipp, Albrich Werner, Kern Lukas, Thiel Sarah, Weber Myriam, Paprotny Matthias, Brugger Silvio D, Risch Lorenz, Bomze David, Flatz Lukas
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunol Immunother 2020; 70:563-568.
17.08.2020Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
17.08.2020Cancer Immunol Immunother 2020; 70:563-568
Hasan Ali Omar, Hundsberger Thomas, Diem Stefan, Müller Stefanie, Pop Oltin, Markert Eva, Müller Joachim, Moulin Alexandre, Ring Sandra, Ackermann Christoph Jakob, Berner Fiamma, Flatz Lukas
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2019; 82:854-861.
23.08.2019BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
23.08.2019J Am Acad Dermatol 2019; 82:854-861
Hasan Ali Omar, Sadik Christian D, Zillikens Detlef, Schmidt Enno, Jochum Wolfram, Mani Bernhard, Cozzio Antonio, Braun Anne, Emtenani Shirin, Hammers Christoph, Abdou Marie-Therese, Diem Stefan, Fässler Mirjam, Berner Fiamma, Ring Sandra S, Bomze David, Flatz Lukas
Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. JAMA Oncol 2019
22.08.2019Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
22.08.2019JAMA Oncol 2019
Bomze David, Hasan Ali Omar, Bate Andrew, Flatz Lukas
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
20.02.2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
20.02.2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
07.12.2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
07.12.2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology
Betschart P, Zumstein V, Hasan Ali O, Schmid H, Abt D. Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology. Urol Int 2017; 100:79-84.
18.11.2017Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology
18.11.2017Urol Int 2017; 100:79-84
Betschart Patrick, Zumstein Valentin, Hasan Ali Omar, Schmid Hans-Peter, Abt Dominik
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
11.09.2017Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
11.09.2017Cancer Immunol Immunother 2017; 67:39-45
Diem Stefan, Hasan Ali Omar, Ackermann Christoph J, Bomze David, Koelzer Viktor H, Jochum Wolfram, Speiser Daniel E, Mertz Kirsten D, Flatz Lukas
GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography
Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. JAAD Case Rep 2016; 2:415-417.
13.10.2016GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography
13.10.2016JAAD Case Rep 2016; 2:415-417
Hasan Ali Omar, Diem Stefan, Aschwanden Josef, Markert Eva, Tasman Abel-Jan, Müller Joachim, Flatz Lukas
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5:e1231292.
19.09.2016Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
19.09.2016Oncoimmunology 2016; 5:e1231292
Hasan Ali Omar, Diem Stefan, Markert Eva, Jochum Wolfram, Kerl Katrin, French Lars E, Speiser Daniel E, Früh Martin, Flatz Lukas